LB Pharmaceuticals Inc Increase (Decrease) in Accounts Payable and Accrued Liabilities
LB Pharmaceuticals Inc (LBRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $16.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $12.54M.
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $3.46M.
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.97M.
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.57M.
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$910.00K, a 118.14% decline from fiscal 2024.
- LB Pharmaceuticals Inc increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $5.02M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.01M 10-Q · filed 2026-08-11 | $17.97M derived: sum of 3 quarters · filed 2026-08-11 | $19.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.46M 10-Q · filed 2026-05-12 | $5.43M derived: sum of 2 quarters · filed 2026-05-12 | $7.00M derived: sum of 3 quarters · filed 2026-05-12 | $5.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.54M derived: sum of 2 quarters · filed 2026-03-26 | $1.98M derived: sum of 3 quarters · filed 2026-08-11 | -$910.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.00K derived: sum of 2 quarters · filed 2026-08-11 | -$2.88M 10-Q · filed 2025-11-06 | -$5.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.45M 10-Q · filed 2026-08-11 | -$7.37M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$2.89M 10-Q · filed 2026-05-12 | -$5.82M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.02M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $7.94M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |